A Convergence-Based Framework for Cancer Drug Resistance.

Cancer Cell
Authors
Keywords
Abstract

Despite advances in cancer biology and therapeutics, drug resistance remains problematic. Resistance is often multifactorial, heterogeneous, and prone to undersampling. Nonetheless, many individual mechanisms of targeted therapy resistance may coalesce into a smaller number of convergences, including pathway reactivation (downstream re-engagement of original effectors), pathway bypass (recruitment of a parallel pathway converging on the same downstream output), and pathway indifference (development of a cellular state independent of the initial therapeutic target). Similar convergences may also underpin immunotherapy resistance. Such parsimonious, convergence-based frameworks may help explain resistance across tumor types and therapeutic categories and may also suggest strategies to overcome it.

Year of Publication
2018
Journal
Cancer Cell
Volume
33
Issue
5
Pages
801-815
Date Published
2018 05 14
ISSN
1878-3686
DOI
10.1016/j.ccell.2018.03.025
PubMed ID
29763622
PubMed Central ID
PMC5957297
Links
Grant list
R01 CA219943 / CA / NCI NIH HHS / United States
U54 CA224068 / CA / NCI NIH HHS / United States